Skip to contentN
Niagen Bioscience, Inc.
N
NAGENiagen Bioscience, Inc. Q2 2013 · 10-Q
Revenue$2.71M$2.71M+1.4% vs Q2 2012 Net Income-$1.02M-$1.02MN/M vs Q2 2012 EPS Diluted-$0.01-$0.01N/M vs Q2 2012 Gross Profit$960,738+25.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Niagen Bioscience, Inc. · CIK 1386570 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,380,258N/M Free Cash Flowderived-$1,411,841N/M Margins · derivedGross margin35.5%+6.9 pt vs Q2 2012
Operating margin-37.4%+111.9 pt vs Q2 2012
Net margin-37.7%+111.8 pt vs Q2 2012
ended Jun 29, 2013 · filed Aug 13, 2013 · 45 d after period end